SCHEMBL6375165

SCHEMBL6375165

CNc1ccc2c(-c3ccccc3)nn(C(=O)OC(C)(C)C)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 2/20 0.51
MAP2K4 P45985 1/20 0.48
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CKS1B P61024 2/20 0.38
SKP1 P63208 2/20 0.38
SKP2 Q13309 2/20 0.38
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
NR1H2 P55055 1/20 0.37
RORC P51449 2/20 0.37
KIT P10721 1/20 0.37
SCD O00767 1/20 0.37
ABCG2 Q9UNQ0 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6370068 0.90 MAP2K4 (0.48) PTGER1MAP2K4KMT2AKDM4EALDH1A1
SCHEMBL6370428 0.86 MAP2K4 (0.47) PTGER1MAP2K4KMT2AKDM4EALDH1A1
SCHEMBL6369571 0.86 MAP2K4 (0.45) PTGER1MAP2K4KMT2AKDM4EALDH1A1
SCHEMBL1513048 0.85 MAP2K4 (0.48) PTGER1MAP2K4KMT2AKDM4EALDH1A1
SCHEMBL6370616 0.84 MAP2K4 (0.57) PTGER1MAP2K4JAK2RORCABCG2
SCHEMBL6370071 0.84 MAP2K4 (0.46) PTGER1MAP2K4KMT2AKDM4EALDH1A1
SCHEMBL6369555 0.84 MAPK8 (0.47) PTGER1MAP2K4RORCMAPT
SCHEMBL6370211 0.84 MAP2K4 (0.44) PTGER1MAP2K4KMT2AKDM4EALDH1A1
SCHEMBL6369557 0.84 MAP2K4 (0.50) PTGER1MAP2K4KMT2AKDM4EALDH1A1
SCHEMBL6370387 0.84 MAP2K4 (0.43) PTGER1MAP2K4KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US disclosed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP disclosed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113370-A1 Therapeutic substituted indazole derivatives NR4A3, CBR3, NR3C2 PTGER1 2789/4885MAP2K4 2785/4885KMT2A 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.